137 related articles for article (PubMed ID: 35538399)
1. Optimized grade group for reporting prostate cancer grade in systematic and MRI-targeted biopsies.
He Y; Shen Q; Fu W; Wang H; Song G
Prostate; 2022 Aug; 82(11):1125-1132. PubMed ID: 35538399
[TBL] [Abstract][Full Text] [Related]
2. Prostate magnetic resonance imaging-targeted biopsy global grade correlates better than highest grade with prostatectomy grade.
Ren J; Melamed J; Taneja SS; Wysock JS; Huang WC; Lepor H; Deng FM
Prostate; 2023 Mar; 83(4):323-330. PubMed ID: 36461793
[TBL] [Abstract][Full Text] [Related]
3. Optimal Method for Reporting Prostate Cancer Grade in MRI-targeted Biopsies.
Deng FM; Isaila B; Jones D; Ren Q; Kyung P; Hoskoppal D; Huang H; Mirsadraei L; Xia Y; Melamed J
Am J Surg Pathol; 2022 Jan; 46(1):44-50. PubMed ID: 34115670
[TBL] [Abstract][Full Text] [Related]
4. A novel biopsy scheme for prostate cancer: targeted and regional systematic biopsy.
He Y; Fan Y; Song H; Shen Q; Ruan M; Chen Y; Li D; Li X; Liu Y; Zhang K; Zhang Q
BMC Urol; 2024 Apr; 24(1):85. PubMed ID: 38614971
[TBL] [Abstract][Full Text] [Related]
5. Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling.
Luzzago S; Petralia G; Maresca D; Sabatini I; Cordima G; Brescia A; Verweij F; Garelli G; Mistretta FA; Cioffi A; Pricolo P; Alessi S; Ferro M; Matei DV; Renne G; de Cobelli O; Musi G
Urol Oncol; 2020 Dec; 38(12):929.e11-929.e19. PubMed ID: 32600928
[TBL] [Abstract][Full Text] [Related]
6. Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillance.
Ploussard G; Beauval JB; Lesourd M; Almeras C; Assoun J; Aziza R; Gautier JR; Loison G; Portalez D; Salin A; Tollon C; Soulié M; Malavaud B; Roumiguié M
World J Urol; 2020 Mar; 38(3):663-671. PubMed ID: 31197523
[TBL] [Abstract][Full Text] [Related]
7. Impact of MRI and Targeted Biopsies on Eligibility and Disease Reclassification in MRI-positive Candidates for Active Surveillance on Systematic Biopsies.
Ploussard G; Beauval JB; Lesourd M; Almeras C; Assoun J; Aziza R; Gautier JR; Loison G; Portalez D; Salin A; Tollon C; Soulié M; Malavaud B; Roumiguié M
Urology; 2020 Mar; 137():126-132. PubMed ID: 31899229
[TBL] [Abstract][Full Text] [Related]
8. Combination MRI-targeted and systematic prostate biopsy may overestimate gleason grade on final surgical pathology and impact risk stratification.
Yu A; Yamany T; Mojtahed A; Hanna N; Nicaise E; Harisinghani M; Wu CL; Dahl DM; Wszolek M; Blute ML; Feldman AS
Urol Oncol; 2022 Feb; 40(2):59.e1-59.e5. PubMed ID: 34544650
[TBL] [Abstract][Full Text] [Related]
9. Concordance of "Case Level" Global, Highest, and Largest Volume Cancer Grade Group on Needle Biopsy Versus Grade Group on Radical Prostatectomy.
Trpkov K; Sangkhamanon S; Yilmaz A; Medlicott SAC; Donnelly B; Gotto G; Shea-Budgell M
Am J Surg Pathol; 2018 Nov; 42(11):1522-1529. PubMed ID: 30080706
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of high-grade prostate cancer pattern on MRI-targeted biopsies: predictors for downgrading and importance of concomitant systematic biopsies.
Manceau C; Fromont-Hankard G; Beauval JB; Lesourd M; Almeras C; Bajeot AS; Gautier JR; Soulié M; Loison G; Salin A; Tollon C; Malavaud B; Roumiguié M; Ploussard G
World J Urol; 2021 Sep; 39(9):3315-3321. PubMed ID: 33609168
[TBL] [Abstract][Full Text] [Related]
11. Gleason Grade Group Concordance between Preoperative Targeted Biopsy and Radical Prostatectomy Histopathologic Analysis: A Comparison Between In-Bore MRI-guided and MRI-Transrectal US Fusion Prostate Biopsies.
Costa DN; Cai Q; Xi Y; Recchimuzzi DZ; Subramanian N; Bagrodia A; Rofsky NM; Roehrborn CG; Hornberger B; Shah RB; Goldberg K; Diaz de Leon A; Pedrosa I
Radiol Imaging Cancer; 2021 Mar; 3(2):e200123. PubMed ID: 33817652
[TBL] [Abstract][Full Text] [Related]
12. Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens.
Rahota RG; Diamand R; Malavaud B; Fiard G; Descotes JL; Peltier A; Beauval JB; Roumeguère T; Roumiguié M; Albisinni S; Ploussard G
BJU Int; 2022 May; 129(5):621-626. PubMed ID: 34358405
[TBL] [Abstract][Full Text] [Related]
13. MRI-Fusion Targeted vs. Systematic Prostate Biopsy-How Does the Biopsy Technique Affect Gleason Grade Concordance and Upgrading After Radical Prostatectomy?
Rührup J; Preisser F; Theißen L; Wenzel M; Roos FC; Becker A; Kluth LA; Bodelle B; Köllermann J; Chun FKH; Mandel P
Front Surg; 2019; 6():55. PubMed ID: 31620444
[No Abstract] [Full Text] [Related]
14. Defining the optimal method for reporting prostate cancer grade and tumor extent on magnetic resonance/ultrasound fusion-targeted biopsies.
Gordetsky JB; Schultz L; Porter KK; Nix JW; Thomas JV; Del Carmen Rodriguez Pena M; Rais-Bahrami S
Hum Pathol; 2018 Jun; 76():68-75. PubMed ID: 29551676
[TBL] [Abstract][Full Text] [Related]
15. Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen.
Radtke JP; Schwab C; Wolf MB; Freitag MT; Alt CD; Kesch C; Popeneciu IV; Huettenbrink C; Gasch C; Klein T; Bonekamp D; Duensing S; Roth W; Schueler S; Stock C; Schlemmer HP; Roethke M; Hohenfellner M; Hadaschik BA
Eur Urol; 2016 Nov; 70(5):846-853. PubMed ID: 26810346
[TBL] [Abstract][Full Text] [Related]
16. A multicentric study on accurate grading of prostate cancer with systematic and MRI/US fusion targeted biopsies: comparison with final histopathology after radical prostatectomy.
Diamand R; Oderda M; Al Hajj Obeid W; Albisinni S; Van Velthoven R; Fasolis G; Simone G; Ferriero M; Roche JB; Piechaud T; Pastore A; Carbone A; Fiard G; Descotes JL; Marra G; Gontero P; Altobelli E; Papalia R; Kumar P; Eldred-Evans D; Giacobbe A; Muto G; Lacetera V; Beatrici V; Roumeguere T; Peltier A
World J Urol; 2019 Oct; 37(10):2109-2117. PubMed ID: 30652213
[TBL] [Abstract][Full Text] [Related]
17. The oncologic risk of magnetic resonance imaging-targeted and systematic cores in patients treated with radical prostatectomy.
Gaffney CD; Tin AL; Fainberg J; Fine S; Jibara G; Touijer K; Eastham J; Scardino P; Laudone V; Vickers AJ; Ehdaie B
Cancer; 2023 Dec; 129(23):3790-3796. PubMed ID: 37584213
[TBL] [Abstract][Full Text] [Related]
18. The role of perilesional and multiparametric resonance imaging-targeted biopsies to reduce the risk of upgrading at radical prostatectomy pathology: A retrospective monocentric study.
Diamand R; Hollans M; Lefebvre Y; Sirtaine N; Limani K; Hawaux E; Abou Zahr R; Mattlet A; Albisinni S; Roumeguère T; Peltier A
Urol Oncol; 2022 May; 40(5):192.e11-192.e17. PubMed ID: 35236622
[TBL] [Abstract][Full Text] [Related]
19. Additive Value of Transrectal Systematic Ventral Biopsies in Combination with Magnet Resonance Imaging/Ultrasound Fusion-Guided Biopsy in Patients with 3 or More Negative Prostate Biopsies.
Maxeiner A; Nest AM; Stephan C; Cash H; Baur ADJ; Fischer T; Kilic E; Piper SK; Nowak CP; Busch J; Miller K; Mang J
Urol Int; 2020; 104(3-4):205-213. PubMed ID: 31801153
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer grading: the effect of stratification of needle biopsy Gleason Score 4 + 3 as high or intermediate grade.
Fanning DM; Kay E; Fan Y; Fitzpatrick JM; Watson RW
BJU Int; 2010 Mar; 105(5):631-5. PubMed ID: 19732053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
